Advance discovery, innovation, and increase the likelihood of trial success with real-world clinical and molecular data, including DNA, RNA and whole slide pathology images.Contact Us
Leverage real-world multimodal data and bioinformatics expertise to identify disease subtypes and power discovery approaches to lead to novel therapeutic opportunitiesRead case study
Analyze your target of interest and identify the most appropriate patient population to evaluate for your therapy programRead case study
Design trials, validate biomarker strategies, define optimal populations to study and assess execution feasibility. Plus, conduct trial simulation and survival analysis to support trial success
Tempus Lens is a comprehensive, real-world, multi-modal data platform that enables Life Science companies to leverage a self-service model to uncover new insights across the research and development spectrum to make smarter decisions and launch molecules more efficiently.
Tempus establishes joint research teams combining disciplines from computational biology, medical, bioinformatics, and machine learning to work alongside your teams with a goal of accelerating therapy development.
Tempus bioinformatics experts help you answer your oncology research questions and meet your research objectives efficiently
Our data licensing partnership provides you with access to de-identified multi-modal data to support iterative research and development objectives using the tools you are most comfortable with
2/3 of the top 20
oncology pharma companies*
We are very pleased to collaborate with Tempus to enhance our data-driven R&D strategy and glean critical insights that will deepen our understanding of complex tumor biology, enhance access to predictive preclinical models, and increase the probability of clinical success across our diverse pipeline.
We are looking forward to working together now and in the future, as we continue to progress our current clinical candidates, test rational combinations, and bring forward new ones, with the goal of getting medicines to patients as quickly as possible.
Our collaboration with Tempus provided valuable insights to prioritize disease indications based on target expression and its relationship with clinical outcomes. The breadth of the Tempus database allowed us to correlate response of many standard therapeutic regimens to target expression to support our clinical trial plans.
Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.
de-identified research records to power scientific discovery
records with imaging data
with matched clinical and molecular data to understand driver mutations and outcomes associations
with full transcriptomic data for interrogating tumor biology and mechanisms of action
database than the Cancer Genome Atlas, which we believe to be the largest public genomic database, based on petabytes of data
Tempus signs strategic collaboration agreement with AstraZeneca to advance oncology therapeuticsRead press release
Tempus announces agreement with Janssen R&D to leverage AI/ML and real-world evidence to enhance the discovery and development of oncology therapiesRead press release
Using molecular signatures of Pancreatic Ductal Adenocarcinoma (PDAC) for targeting discoveryRead case study
Pairing sequencing, analytics, and data licensing to uncover new R&D insightsRead case studies
Thank you for contacting Tempus. We will respond shortly.